Lupin receives FDA approval for generic Clobex® Spray, 0.05%

Lupin announced that it has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.'s Clobex® Spray, 0.05%.

Lupin's Clobetasol Propionate Spray, 0.05% is the generic equivalent of Galderma Laboratories, L.P.'s Clobex® Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.

Clobetasol Propionate Spray, 0.05% had annual sales of approximately USD 30.5 million in the US (IQVIA MAT January 2018).

Shares of LUPIN LTD. was last trading in BSE at Rs.748.1 as compared to the previous close of Rs. 739.8. The total number of shares traded during the day was 75327 in over 1788 trades.

The stock hit an intraday high of Rs. 752 and intraday low of 742. The net turnover during the day was Rs. 56361090.

Source : Equity Bulls

Keywords